News / Health

India's Cancer-Drug Ruling Likely to Have Global Impact

People gather at Novartis India headquarters in Mumbai April 1, 2013.
People gather at Novartis India headquarters in Mumbai April 1, 2013.
Jessica Berman
A landmark ruling by India’s high court this week struck down a bid by Swiss drugmaker Novartis to extend patent protection for its cancer drug, Glivec.

The decision is seen as a blow to Western pharmaceutical companies seeking to protect their financial interests.  Experts say it could embolden pharmaceutical companies in other countries hoping to produce generic versions of name-brand medications.  That could mean wider availability of the less expensive drugs throughout the developing world.

India is not the only country manufacturing generic versions of important and popular drugs.  Argentina and the Philippines have passed strict laws limiting the patent protections on name-brand drugs developed by U.S. and European pharmaceutical companies, including medications to treat HIV, the virus that causes AIDS.
 
Patents allow companies that develop a drug to maintain exclusive rights to sell it at a higher price for an extended period of time, in order to recoup their research and development costs.  Western pharmaceutical firms say those returns are essential to their ability to develop new and better medicines.

In the India case, which has been wending its way through the country’s judicial system for 7 years, Novartis failed to convince the high court that it had made changes to Glivec, its widely used leukemia drug, significant enough to warrant extending its patent and exclusive marketing rights.

Tahir Amin is a director of the New York-based Initiative for Medicines, Access and Knowledge, a non-profit organization which works on patent cases to increase access to drugs.  Amin says the India case is likely to have far-reaching implications.

“Globally, I think a number of countries will look at this and say, “Well India stood its ground,” and will also realize that actually if India is standing its ground, even though it has a stronger geopolitical standing and can actually probably stand up to the U.S. and Europe a little bit more, I think other countries will also take notice of this and say, 'This is in our public interest and health interest to adopt patent laws that are somewhat similar,'” said Amin.

India exports some $10 billion worth of generic drugs every year and, along with China, produces about 80 percent of the ingredients that are used in the manufacture of drugs in the United States. India also produces generic versions of many popular drugs.

Novartis and other drug companies say the Indian court ruling may force them to pull their research dollars out of India.

Mark Grayson is a spokesman for the Pharmaceutical Research and Manufacturers of America, or PhRMA, which represents drug manufacturers.
 
“We’re disappointed in this ruling because we believe that this just shows a further deteriorating innovation environment in India," said Grayson.

Generic drug versions can be sold at a fraction of the cost of brand-name drugs.  For example, Glivec can cost a patient around $70,000 a year, while the Indian generic versions costs around $2,500.
 
Grayson believes patients who can afford a drug like Glivec should pay full price.

“We believe we need to find ways to get economies that are growing to pay their fair share for the new medicines and the cost that it takes to develop a lot of this medicine," he said.

Grayson says 95 percent of the patients in India who can't afford Glivec can get it for free through a so-called "compassionate care" program run by Novartis.

But Tahir Amin of Initiatives for Medicine says cancer patients have reported that it has been difficult to obtain those free drugs.

“If you are going to be at the whim of philanthropy, then I think most people are not going to get drugs," he said. "And we’ve seen that in other cases as well, where they say we have access programs and so on and so forth.  But only a certain percentage of the population or countries get it.”

But with drug development costs sometimes topping $1 billion, PhRMA’s Grayson fears that India’s patent ruling and others that may follow could slow the pace at which critically needed new drugs come to market.

You May Like

Video On the Scene: In Gaza, Darkness Brings Dread and Death

Palestinians fear nighttime raids, many feel abandoned by outside world, VOA's Scott Bobb reports More

African Small Farmers Could Be Key to Ending Food Insecurity

Experts say providing access to microloans, crop insurance, better storage facilities, irrigation, road systems and market information could enable greater production More

University of Michigan Wins Solar Car Race

Squad guided its student-designed solar-powered vehicle to fifth consecutive time victory in eight-day bi-annual American Solar Challenge More

Featured Videos

Your JavaScript is turned off or you have an old version of Adobe's Flash Player. Get the latest Flash player.
Vietnamese Staging Chinese Product Boycott After Oil Rig Spati
X
Reasey Poch
July 28, 2014 7:18 PM
China recently pulled an oil rig from an area of the disputed South China Sea that Vietnam also claims. Despite the action, the incident has had a lingering effect on consumers in Vietnam. VOA's Reasey Poch reports from Hanoi on an effort to boycott Chinese products.
Video

Video Vietnamese Staging Chinese Product Boycott After Oil Rig Spat

China recently pulled an oil rig from an area of the disputed South China Sea that Vietnam also claims. Despite the action, the incident has had a lingering effect on consumers in Vietnam. VOA's Reasey Poch reports from Hanoi on an effort to boycott Chinese products.
Video

Video ESA Spacecraft to Land on a Comet

After a long flight through deep space, a European Space Agency probe is finally approaching its target -- a comet millions of kilometers away from earth. Scientists say the mission may lead to some startling discoveries about the origins of the water on earth. VOA’s George Putic has more.
Video

Video Young Africans Arrive in US for Leadership Program

President Barack Obama's Young African Leadership Initiative has brought hundreds of young Africans to the United States for a six-week program aimed at building their knowledge and skills in fields such as public administration and business. Out of the 50,000 young Africans who applied for the program, just one percent was accepted. VOA's Laurel Bowman caught up with some of those who made the cut and has this report.
Video

Video In Honduras, Amnesty Rumors Fuel US Migration Surges

False rumors in Central America are fueling the current surge of undocumented young people being apprehended at the U.S. border. The inaccurate claims suggest the U.S. will give amnesty to young migrants from the region. As VOA's Brian Padden reports from Honduras, these rumors trace back to President Obama's 2012 executive order to halt deportations for some young undocumented immigrants already living in the United States.
Video

Video Students in Business for Themselves

They're only high school students, but they are making accessories for shoes, fabricating backpacks and doing product photography - all through their own businesses. It's the result of a partnership between a non-profit organization that teaches entrepreneurship and their schools. VOA's Mike O'Sullivan and Deyane Moses met the budding entrepreneurs near Los Angeles.
Video

Video Astronauts Train in Underwater Lab

In the world’s only underwater laboratory, four U.S. astronauts train for a planned visit to an asteroid. The lab - called Aquarius- is located five kilometers off Key Largo, in southern Florida. Living in close quarters and making excursions only into the surrounding ocean, they try to simulate the daily routine of a crew that will someday travel to collect samples of a rock orbiting far away from earth. VOA’s George Putic has more.

AppleAndroid